BibbInstruments

BibbInstruments ROE

The Return on Equity (ROE) of BibbInstruments (BIBB.SL) as of Oct 20, 2026 is -38.82 %. In the previous year, Return on Equity (ROE) was -44.78 % — a change of -13.30% (higher).

ROE

-38.82 %

YoY

-13.30%

Last updated:

In 2025, BibbInstruments's return on equity (ROE) was -38.82 %, a -13.30% increase from the -44.78 % ROE in the previous year.

The BibbInstruments ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2018
-31.04 SEK
Jan 1, 2019
-53.56 SEK
Jan 1, 2020
-40.08 SEK
Jan 1, 2021
-47.72 SEK
Jan 1, 2022
-35.49 SEK
Jan 1, 2023
-35.14 SEK
Jan 1, 2024
-44.78 SEK
Jan 1, 2025
-38.82 SEK
The BibbInstruments ROE history
YEARROEYoY
-38.82 %-13.30%
-44.78 %+27.44%
-35.14 %-1.00%
-35.49 %-25.62%
-47.72 %+19.05%
-40.08 %-25.17%
-53.56 %+72.58%
-31.04 %+7.09%
-28.98 %-44,732.03%
0.06 %-85.97%
0.46 %-91.34%
5.35 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BibbInstruments Stock analysis

What does BibbInstruments do? BiBBInstruments AB generates revenue through the development and sale of diagnostic instruments for early cancer detection, primarily utilizing its EndoDrill technology platform. The company markets specific products including EndoDrill GI Upper for stomach biopsies, EndoDrill GI Lower for intestinal biopsies, EndoDrill GI Lung for lung biopsies, EndoDrill Therapy for organ displacement procedures, EndoDrill Needle for breast biopsies, and EndoDrill Model X for multiple applications. These instruments are sold to hospitals with endoscopy specialist centers and surgical wards, focusing on Scandinavian countries as their primary market. The company's portfolio targets medical professionals requiring precise diagnostic tools for deep skin tissue analysis and treatment procedures. The business model centers on selling specialized biopsy instruments that enable early cancer diagnosis in various organs. EndoDrill GI Upper, GI Lower, and GI Lung are designed for gastrointestinal and respiratory tract biopsies, while EndoDrill Therapy facilitates treatment procedures involving stents and conductors. EndoDrill Needle specifically addresses breast biopsy needs, and EndoDrill Model X serves as an independent research project covering multiple anatomical areas. All products are distributed through hospital networks specializing in endoscopy and surgery. BiBBInstruments AB's revenue streams are derived from direct sales of its diagnostic instrument portfolio to healthcare institutions. The company focuses on Scandinavian countries for distribution, targeting hospitals with specialized endoscopy centers and surgical departments. The EndoDrill technology platform underpins all products, providing a unified approach to early cancer detection and treatment procedures across different medical specialties. BibbInstruments is one of the most popular companies on Eulerpool.

ROE Details

Decoding BibbInstruments's Return on Equity (ROE)

BibbInstruments's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing BibbInstruments's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

BibbInstruments's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in BibbInstruments’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about BibbInstruments stock

Return on Equity (ROE) of BibbInstruments is -38.82 % in 2025.

Return on Equity (ROE) of BibbInstruments changed from -44.78 % to -38.82 %, representing a -13.30% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) BibbInstruments since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s BibbInstruments with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — BibbInstruments

All Key Metrics — BibbInstruments